Investigational drug · Phase 3
Troriluzole
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obsessive-Compulsive Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
15
Any phase or sponsor naming "Troriluzole"
First trial start
2020
Dec 22, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Troriluzole", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obsessive-Compulsive Disorder
Largest trials
Live from ClinicalTrials.gov: studies naming "Troriluzole" as an intervention, largest first.
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPivotal-lookingRecruiting
Global Coalition for Adaptive ResearchAcademic, hospital or other
NCT03970447 · 2,250 participants (planned) · Start Jul 30, 2019 · Primary completion Jun 2028
Drug: Temozolomide; Lomustine and 8 more · For: Glioblastoma
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 63 sites in all
Biohaven Therapeutics Ltd.Industry
NCT06529146 · 909 participants · Start Mar 18, 2019 · Primary completion Sep 6, 2024
Drug: BHV-4157 · For: Spinocerebellar Ataxias
Sites: New Haven, Connecticut
- Randomized Trial of Adult Participants With Generalized Anxiety DisorderPivotal-lookingCompleted
Biohaven Pharmaceuticals, Inc.Industry
NCT03829241 · 881 participants · Start Feb 19, 2019 · Primary completion Jan 14, 2020
Drug: Troriluzole; Placebo · For: Generalized Anxiety Disorder
Sites: Little Rock, Arkansas; Colton, California; Encino, California · 53 sites in all
- Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive DisorderPivotal-lookingTerminated
Biohaven Pharmaceuticals, Inc.Industry
NCT04708834 · 772 participants · Start Mar 30, 2021 · Primary completion Feb 13, 2026
Drug: Troriluzole (BHV-4157) · For: Obsessive Compulsive Disorder
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 175 sites in all
- A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive DisorderPivotal-lookingCompleted
Biohaven Pharmaceuticals, Inc.Industry
NCT04693351 · 589 participants · Start Jan 29, 2021 · Primary completion Apr 29, 2025
Drug: Troriluzole; Placebo · For: Obsessive-Compulsive Disorder
Sites: Phoenix, Arizona; Culver City, California; La Jolla, California · 89 sites in all
- Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive DisorderPivotal-lookingCompleted
Biohaven Pharmaceuticals, Inc.Industry
NCT04641143 · 456 participants · Start Dec 22, 2020 · Primary completion Oct 27, 2025
Drug: Troriluzole; Placebo · For: Obsessive-Compulsive Disorder
Sites: Chandler, Arizona; Phoenix, Arizona; Bellflower, California · 73 sites in all
- Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive DisorderPivotal-lookingCompleted
Biohaven Pharmaceuticals, Inc.Industry
NCT03299166 · 426 participants · Start Dec 19, 2017 · Primary completion Jun 2, 2020
Drug: Troriluzole; Placebo · For: Obsessive-Compulsive Disorder
Sites: Chandler, Arizona; Little Rock, Arkansas; Garden Grove, California · 57 sites in all
- Study of BHV-4157 in Alzheimer's DiseasePivotal-lookingCompleted
Biohaven Pharmaceuticals, Inc.Industry
NCT03605667 · 350 participants · Start Jul 31, 2018 · Primary completion Dec 15, 2020
Drug: troriluzole; Placebo oral capsule · For: Alzheimer Disease
Sites: Phoenix, Arizona; Sun City, Arizona; Fullerton, California · 44 sites in all
- Troriluzole in Adult Participants With Spinocerebellar AtaxiaPivotal-lookingCompleted
Biohaven Pharmaceuticals, Inc.Industry
NCT03701399 · 299 participants · Start Mar 8, 2019 · Primary completion Feb 18, 2022
Drug: troriluzole; Placebo · For: Spinocerebellar Ataxias; Spinocerebellar Ataxia Type 1; Spinocerebellar Ataxia Type 2 and 5 more
Sites: Phoenix, Arizona; Long Beach, California; Los Angeles, California · 23 sites in all
- Trial in Adult Participants With Spinocerebellar Ataxia (SCA)Pivotal-lookingCompleted
Biohaven Pharmaceuticals, Inc.Industry
NCT02960893 · 141 participants · Start Dec 15, 2016 · Primary completion Aug 18, 2017
Drug: Troriluzole; Placebo and 1 more · For: Spinocerebellar Ataxias; Spinocerebellar Ataxia Genotype Type 1; Spinocerebellar Ataxia Genotype Type 2 and 5 more
Sites: Phoenix, Arizona; Long Beach, California; Los Angeles, California · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Troriluzole attenuates opioid intake, reinforcing efficacy, seeking behaviours, physical dependence and antinociceptive tolerance in rats.
Galaj E, Inan S, Bi GH, et al. · Br J Pharmacol 2026
- Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer's disease.
Qiu Y, Jacobs DM, Messer K, et al. · Alzheimers Res Ther 2025
- Measurement Properties of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia.
Potashman MH, Popoff E, Powell LC, et al. · Neurol Ther 2025
- Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg-AD mice.
Pfitzer J, Pinky PD, Perman S, et al. · J Neurochem 2025
- New horizons for obsessive-compulsive disorder drug discovery: is targeting glutamate receptors the answer?
Grassi G, Scillitani E, Cecchelli C · Expert Opin Drug Discov 2024
- Psychometric Validation of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) in Patients With Spinocerebellar Ataxia.
Potashman M, Popoff E, Powell L, et al. · Cerebellum 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.